Table 1. Baseline characteristics (n=21).
| Median age, years (range) |
74 (57–89) |
| Time since diagnosis, months (range) |
120 (17–331) |
| PSA (ng ml−1), median (range) |
238 (8.0–2.361) |
| Time on ADTa, months (range) |
60 (17–240) |
| Alkaline phosphatase (U l−1), median (range) |
104 (57–869) |
| Analgesic use, n (%) |
7 (33) |
|
Site of metastases, n (%) | |
| Bone | 6 (29) |
| Bone and visceral | 11 (52) |
| Bone and lymph node | 3 (14) |
| Lymph node |
1 (5) |
|
ECOG performance status, n (%) | |
| 0 | 10 (48) |
| 1 | 10 (48) |
| 2 |
1 (5) |
|
Gleason score, n (%) | |
| ⩾7 | 17 (81) |
| <7 | 3 (14) |
| Unknown | 1 (5) |
Abbreviations: ADT=androgen deprivation therapy; ECOG=eastern Cooperative Oncology group; PSA=prostatic-specific antigen.
a
Before starting the study.